--- title: "The medical innovation ETF is trending upward, with continuous positive policies being released" type: "News" locale: "en" url: "https://longbridge.com/en/news/278648211.md" description: "The medical innovation ETF is trending upwards, with continuous positive policies being released. The CSI Medicine and Medical Device Innovation Index rose by 0.01%, and constituent stock NHU increased by 4.66%. Jiangsu Province has released an innovation development plan for the brain-computer interface industry, aiming to cultivate 30 application scenarios by 2030. Biomedicine has been elevated to an emerging pillar industry, with an estimated total of 157 innovative drug transactions expected by 2025, amounting to approximately USD 135.7 billion. The medical innovation ETF closely tracks the CSI Medicine and Medical Device Innovation Index, reflecting the overall performance of listed pharmaceutical and medical device companies. Risk warning: Investment should be cautious" datetime: "2026-03-11T02:34:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278648211.md) - [en](https://longbridge.com/en/news/278648211.md) - [zh-HK](https://longbridge.com/zh-HK/news/278648211.md) --- # The medical innovation ETF is trending upward, with continuous positive policies being released As of March 11, 2026, 10:19, the CSI Medicine and Medical Device Innovation Index (931484) rose by 0.01%. Among the constituent stocks, NHU increased by 4.66%, Xingqi Eye Hospital rose by 4.63%, Jinbo Biotechnology climbed by 3.17%, Huitai Medical went up by 1.89%, and Zhejiang Medicine increased by 1.43%. The Medical Innovation ETF (516820) rose by 0.28%, with the latest price reported at 0.36 yuan. In terms of news, Jiangsu issued the "Action Plan for the Innovative Development of the Brain-Computer Interface Industry in Jiangsu Province." It proposes to establish no less than two provincial-level brain-computer interface industrial clusters by 2027 and to cultivate 2-3 leading enterprises with domestic and international influence by 2030; by 2030, it aims to nurture no less than 30 typical application scenarios of "brain-computer interface + consumption." Previously, brain-computer interfaces were first included in the "2026 Government Work Report," signaling strong policy support at the national level; at the same time, the biopharmaceutical sector has been elevated to the status of an "emerging pillar industry." Aijian Securities pointed out that according to statistics from the Pharmaceutical Cube, the total number of License-out transactions for innovative drugs in China reached 157 in 2025, with a total amount of approximately 135.7 billion USD, and the upfront payment reached 7 billion USD, doubling compared to 2024. With the combination of policy signals and the continuous release of industrial innovation capabilities, China's biopharmaceutical industry is entering a new cycle of high-quality development and gradually becoming an important participant in the global pharmaceutical innovation system, while also becoming a new pillar and engine for national economic development. The Medical Innovation ETF closely tracks the CSI Medicine and Medical Device Innovation Index. The CSI Medicine and Medical Device Innovation Index selects 30 publicly listed companies with good profitability, certain growth potential, and research and innovation capabilities from the pharmaceutical and healthcare industry as index samples, reflecting the overall performance of publicly listed companies in the pharmaceutical and medical device sectors that combine profitability and growth. Data shows that as of February 27, 2026, the top ten weighted stocks in the CSI Medicine and Medical Device Innovation Index (931484) are WuXi AppTec, Mindray Medical, Heng Rui Medicine, Aier Eye Hospital, Pian Zai Huang, NHU, East China Pharmaceutical, Kanglong Huacheng, Ailisi, and Dong'e Ejiao, with the top ten weighted stocks accounting for a total of 63.75%. Risk Warning: Funds carry risks, and investment requires caution. The fund manager promises to manage and utilize fund assets based on the principles of honesty, credit, diligence, and responsibility, but does not guarantee that this fund will definitely make a profit, nor does it guarantee a minimum return. The fund manager reminds investors of the "buyer bears the risk" principle in fund investment; after making an investment decision, the investment risks arising from the fund's operating status and changes in net value are borne by the investors themselves. The past performance of the fund and its net value does not indicate its future performance. The performance of other funds managed by the fund manager does not constitute a guarantee of this fund's performance. Investors purchasing funds may share in the profits generated by the fund's investments according to their holdings, but may also bear losses arising from the fund's investments. Investors should carefully read the "Fund Contract," "Prospectus," and other legal documents of the fund, fully understand the risk-return characteristics and product features of this fund, and judge whether the fund is suitable for their risk tolerance based on their investment objectives, investment horizon, investment experience, and asset status Rationally assess the market and make investment decisions with caution. The relevant information in this material is sourced from publicly available materials deemed reliable by the fund manager. The relevant opinions, evaluations, and forecasts reflect current judgments and may change in the future. Any market opinions contained in this material are based on corresponding assumptions, and any assumptions may change at any time. The fund manager does not commit to or guarantee that any predictive market opinions will necessarily be realized. The individual stocks mentioned in the material do not constitute investment recommendations or advice. The fluctuations in the secondary market of ETF funds do not represent the actual return rate of the fund; investors should pay attention to the risks of price volatility in the market ### Related Stocks - [002001.CN](https://longbridge.com/en/quote/002001.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [159898.CN](https://longbridge.com/en/quote/159898.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [160635.CN](https://longbridge.com/en/quote/160635.CN.md) ## Related News & Research - [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md) - [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md) - [12:00 ETVilla Albertine Announces the Lafayette Fellowship, a Prestigious New Graduate Scholarship in France for America's Emerging Leaders](https://longbridge.com/en/news/287248753.md) - [01:00 ETNational Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation](https://longbridge.com/en/news/286359416.md) - [GE HealthCare Technologies Sticks to Growth Story After Inflation-Driven Guidance Cut](https://longbridge.com/en/news/286668803.md)